Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.84 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608978 | 0.91 | TLR8 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL18109543 | 0.91 | TLR8 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL18109292 | 0.91 | TLR8 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL18109290 | 0.91 | TLR8 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL30608943 | 0.91 | TLR8 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL13975728 | 0.85 | KCNH2 (1.00) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975810 | 0.85 | KCNH2 (1.00) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL15502363 | 0.84 | KCNH2 (1.00) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975848 | 0.84 | KCNH2 (1.00) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL19924270 | 0.83 | TLR8 (0.72) | KCNH2TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4146282-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021226440-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226440-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | KCNH2 4852/4885TLR8 2187/4885TLR7 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.